Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
LEXINGTON, Mass., Aug. 31, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a trial-in-progress poster describing preliminary clinical data from the dose escalation stage of CA-170 Phase 1 clinical trial at the European Society for Medical Oncology (ESMO) 2017 Congress. The conference will take place September 8-12 in Madrid. CA-170, an oral small molecule targeting the immune checkpoints PDL1 and VISTA, is in development for the treatment of patients with advanced solid tumors or lymphomas.
Additional information on the presentation can be found below and can be accessed at www.esmo.org.
CA-170 Poster Presentation:
| Date/Time: | Monday, Sept. 11, 9:15 AM – 10:45 AM CEST |
| Abstract Number: | 1141PD |
| CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in | |
| Presentation Title: | pre-clinical models and promotes T cell activation in Phase 1 study |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
